IGA score of cleared (0) or minimal disease (1) was achieved by a significantly greater proportion of those in the guselkumab vs placebo group, 74.2% vs 12.4%, respectively. Arexvy is currently ...
Arexvy is currently approved for active immunization for the prevention of LRTD caused by RSV in individuals 60 years of age and older, and those 50 to 59 years of age who are at increased risk ...
Preliminary data were announced from 2 clinical trials evaluating Arexvy (respiratory syncytial virus [RSV] vaccine, adjuvanted) in a broader population of adults at increased for RSV disease. Arexvy ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress ... rebranding to its current name in 2022. GSK now operates in more than 75 countries and has 37 manufacturing ...
GSK plc announced new preliminary data for Arexvy (respiratory syncytial virus vaccine ... undergoing review in other countries – including Japan. The proposed trade name remains subject to regulatory ...
Graham Parry has given his Sell rating due to a combination of factors affecting GlaxoSmithKline’s Arexvy vaccine. The challenges highlighted include the limited effectiveness of a single shot ...
US pharma major GSK (LSE: GSK) yesterday announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased risk for RSV-LRTD due ...
GSK’s Arexvy—which became the industry’s first FDA-approved RSV shot in May 2023—was greenlit for use in adults aged 50 to 59 in June 2024. On Thursday, GSK unveiled Phase IIIb data showing that a ...
GSK plc (LSE/NYSE: GSK), the global healthcare company, today announced preliminary data from ongoing clinical trials that suggest its respiratory syncytial virus (RSV) vaccine, Arexvy, may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback